Otros idiomas Rallybio Corporation

Acciones

RLYB

US75120L1008

Tiempo real estimado Cboe BZX Otros sitios de cotización 19:40:45 24/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,56 ^USD	-3,11 %		-10,45 %	-33,68 %

15/05	RALLYBIO CORPORATION : JPMorgan Chase revisa su opinión y se vuelve a Neutral	ZM
09/05	Rallybio Corporation presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Rallybio : The Citizens JMP Life Sciences Conference	15/05
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates	09/05
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference	07/05
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting	17/04
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	17/04
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB	15/04
Top Premarket Decliners	12/04
US Equity Markets Close Mixed After March Producer Price Inflation Data	11/04
Sector Update: Health Care Stocks Softer Late Afternoon	11/04
Aktien New York: Dow erholt sich vor Start in die Berichtssaison	11/04
Top Midday Gainers	11/04
Aktien New York: Dow schwächer vor Start in die Berichtssaison	11/04
Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet	11/04
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	11/04
Top Premarket Gainers	11/04
Rallybio Corporation Announces Collaboration with Johnson & Johnson	10/04
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)	10/04
Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	10/04
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting	01/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Rallybio Corporation

Acciones

RLYB

US75120L1008

Otros idiomas

Filtros